Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 752 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sodium chloride solution 0.9% (saline) Clear all
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease

NCT03808103
View directory record Official record
Conditions
Crohn Disease
Interventions
Placebo, Bacteriophage preparation
Biological
Lead sponsor
Intralytix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
2
States / cities
Lutherville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 13, 2026, 5:38 PM EDT
Not listed Phase 1Phase 2 Interventional

Siltuximab in Schizophrenia

NCT02796859
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Siltuximab, normal saline
Drug
Lead sponsor
Brian Miller
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Not applicable Interventional Results available

Effect of Postop Steroids on Cardiovascular/Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass

NCT01595386
View directory record Official record
Conditions
Heart Disease Congenital Complex
Interventions
Hydrocortisone, Normal Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 28 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 13, 2026, 5:38 PM EDT
Terminated Phase 2 Interventional Results available

High Dose Intravenous Ascorbic Acid in Severe Sepsis

NCT02734147
View directory record Official record
Conditions
Sepsis
Interventions
Ascorbic Acid, Normal Saline
Drug · Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 13, 2026, 5:38 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants

NCT02620761
View directory record Official record
Conditions
Patent Ductus Arteriosus (PDA), Acute Kidney Injury (AKI)
Interventions
Fenoldopam, 0.9%NS
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
0 Days to 28 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 13, 2026, 5:38 PM EDT
Not yet recruiting Not applicable Interventional

Cognitive Enhancement in Recurrent Depression (The COG-D-R Study)

NCT07527273
View directory record Official record
Conditions
Aging, Depression, Cognitive Symptoms
Interventions
Depression Cognitive Training, Non-Specific Cognitive Training, tDCS (active stimulation), tDCS (sham stimulation)
Behavioral · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

NCT04350138
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Meningococcal Group B Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
2,606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults

NCT03844386
View directory record Official record
Conditions
HIV-1 Infection
Interventions
MVA.tHIVconsv3, MVA.tHIVconsv4, Placebo
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?

NCT02939742
View directory record Official record
Conditions
PPROM, Respiratory Distress Syndrome in Premature Infants
Interventions
Betamethasone, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Crizanlizumab for Treating COVID-19 Vasculopathy

NCT04435184
View directory record Official record
Conditions
COVID-19
Interventions
Crizanlizumab, 0.9% saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 13, 2026, 5:38 PM EDT
Terminated Phase 1 Interventional Results available

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT04478994
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
TEPEZZA, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Immunomodulatory Properties of Ketamine in Sepsis

NCT01089361
View directory record Official record
Conditions
Sepsis
Interventions
Ketamine, Normal Saline placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

NCT04776317
View directory record Official record
Conditions
COVID-19
Interventions
ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 13, 2026, 5:38 PM EDT
Terminated Phase 2 Interventional Results available

Tranexamic Acid and Thromboelastography During Cesarean Delivery

NCT02026297
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Tranexamic Acid, Placebo; Normal Saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients

NCT03821272
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
PepCan, Placebo
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

NCT04897412
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, Placebo
Drug · Other
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Chicago, Illinois • Omaha, Nebraska • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 13, 2026, 5:38 PM EDT
Not yet recruiting Phase 4 Interventional

Pain with Differing Intraperitoneal Washes At the End of Laparoscopic Gynecologic Surgery

NCT06842771
View directory record Official record
Conditions
Laparoscopic Adnexal Surgery
Interventions
Normal Saline (0.9% NaCl), Marcaine hydrochloride without epinephrine 0.5%
Other · Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

NCT03122223
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 13, 2026, 5:38 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Intrauterine Device Insertion Pain Management

NCT06951191
View directory record Official record
Conditions
IUD Insertion Pain, IUD Insertion
Interventions
Benzocaine 20%, Lidocaine 2%, Sham injection, Saline 0.9%
Drug · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Effectiveness Of Intravenous TXA on Reducing Perioperative Blood Loss For Patients Undergoing PAO

NCT03823417
View directory record Official record
Conditions
Bleeding
Interventions
Tranexamic Acid, Normal saline
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation

NCT03133767
View directory record Official record
Conditions
Fluid Loss, Symptom Complex, Triple, Emergencies
Interventions
Lactated Ringer Solution, Normal Saline 0.9% Infusion Solution Bag
Drug
Lead sponsor
Nicholas M Mohr
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Not applicable Interventional Results available

Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?

NCT02276495
View directory record Official record
Conditions
Pain Management
Interventions
ACB Control - 20 ml saline injection for ACB, ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block, Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Other · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 13, 2026, 5:38 PM EDT
Withdrawn Phase 2 Interventional

Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia

NCT03852992
View directory record Official record
Conditions
Male Pattern Hair Loss, Androgenetic Alopecia, Male Pattern Baldness
Interventions
Post-Laser Minoxidil 2%, At-Home Minoxidil 5%, Laser, Post-laser 5mg minoxidil, Post-laser 10mg minoxidil, Post-laser 20mg minoxidil
Drug · Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 13, 2026, 5:38 PM EDT